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1050-38 Disparate Clinical Outcomes of Diabetic and 
Nondiabetic Patients Undergoing Primary Angioplaaty 
for Acute Myocardial Infarction: Is Diabetes Mellitus an 
Independent Predictor of Poor Outcome? 
Kishore J. Hariai, Cindy L. Gdnes, Tuan Pham, Gregg W. Stone, Harish Chandra, Judith 
Boura, Luiz Mattos, David Cox, Lorelei L. Grines, William W. O'Neill, Primary Angioplasty 
in Myocardial Infarction StudyGroup, William Beaumont Hospital, Royal Oak, Michigan. 
Background: Prior studies examining the effect of diabetes mellitus (DM) on outcome 
after primary angioplasty in AMI are limited by small size & have been inconclusive. 
Methods: We compared baseline characteristics & angiographic & clinical outcomes 
between DM (n=626) & non-DM (n=3116) pts enrolled in the PAMI trials. 
Results: DM pts were older (64 vs 60 yrs), more likely to be female (37 vs 25%), present 
with Killip class > 1 (18 vs 13%), & have a history of HTN (63 vs 44%), heart failure (6 vs 
2%), CVA (9 vs 5%), PVD (12 vs 5%), prior MI (20 vs 14%), prior PTCA (15 vs 9%), & 
prior CABG (7 vs 4%). They were less likely to be smokers (28 vs 43%) & have SBP 
<100 mmHg (27 vs 32%). DM pts had longer onset-to-presentation (172 vs 156 min), & 
door-to-balloon times (183 vs 156 min) & lower LVEF (47 vs 49%), but were more likely 
to have baseline TIMl-flow >1 (36 vs 30%; p<0.05 for all). They had more multivessel dis- 
ease (60 vs 47%, p<0.0001) but were equally likely to have angiographic thrombus (64 
vs 63%), anterior MI (43 vs 42%), & less likely to undergo PCI (88 vs 91%, p=0.01). 
Technical success (95 vs 97%), stent use (31 vs 34%) & final TIMI-3 flow (92 vs 93%) 
were similar between groups. DM pts were more likely to develop pulmonary edema (8 
vs 5%), sustained hypotension (8 vs 6%), & to require dialysis (1.4 vs 0.3%) & CABG (11 
vs 8%) during hospitalization. They had higher rates of in-hospital death (4.6 vs 2.6%, 
p=0.005), but similar rates of reinfarction (1.3 vs 0.9%), ischemic TVR (I-TVR; 2.0 vs 
3.2%), & MACE (7 vs 6%). During 1-yr follow-up, DM pts had similar rates of I-TVR (16 
vs 19%), but higher reinfarction (6 vs 3%, p=0.005), death (10 vs 6%, p=0.001), & MACE 
(25 vs 20%; p=0.014). In multivariate analysis, DM was independently associated with 1- 
yr reinfarction (OR = 1.9; CI = 1.2 - 2.9), but not with in-hospital death (OR=1.1, C1=0.6- 
2.0) or MACE (OR=l.0, C1=0.7-1.5), or 1-yr death (OR=1.4, C1=0.96-2.1) or MACE 
(OR=1.1, C1=0.9-1.4). 
Conclusions: DM pts undergoing primary angioplasty have worse baseline clinical fea- 
tures and unfavorable in-hospital & 1-year outcomes compared to non-DM pts. The pres- 
ence of DM independently increases the risk of reintarction during 1-yr follow-up, though 
the higher death rate may be explained by comorbid risk factors, 
1050-39 Does Abciximab and Stenting Improve Outcomes in 
Elderly Patients Undergoing Primary PCl for Acute 
Myocardial Infarction: Data From the CADILLAC Trial 
Giulio Guaoliumi. David A. Cox, Cindy Grines, Eulogio Garcia, Thomas Stuckey, James 
Tcheng, John Pasquini, John Carroll, Alexandra Lansky, Gregg W. Stone, Ospeda/i 
Riunite Di Bergamo /ta/y, Bergamo, /ta/y, The Cardiovascular Research Foundation, New 
York Ci~ New York. 
Background: Elderly patients (75 yrs or greater) constitute a growing subset of patients 
presenting with AMI. Previous trials have demonstrated worse acute and long-term out- 
comes in elderly patients with AMI. The CADILLAC Trial did not exclude patients on the 
basis of age and utilized lower profile stents along with abciximab. Whether newer stents 
and 2b3a inhibitors improve outcomes in eldedy patients with AMI is unknown. 
Methods: 2082 AMI patients of any age w/in 12 hrs of symptom onset (excl. cardiogenic 
shock) were randomized at 76 sites to primary PTCA, PTCA with abcix, stent alone, or 
stent with abcix. 
Results: Elderly patients (75 yrs or >) comprised 13.1% (273/2082) of all patients 
enrolled in the CADILLAC trial. At 30 days, elderly patients had higher mortality (4.8% vs 
1.6%,p=.002) and MACE (9.2% vs 5,t%,p=.012). Elderly pts assigned to stenting had 
higher mortality at 30 days compared to stent pts <75 yrs (6.6% vs 1.6%, p=.002). At 1- 
year elderly pts, demonstrated greater mortality (11% vs 3%, p<.001) and increased 
MACE (21.6% vs 15.6%,p=.016). 
Conclusion: Elderly patients with AMI continue to have worse Outcomes even with 
adjunctive 2b3a inhibitors and contemporary low-profile stents. A 1-year mortality of 11% 
in elderly patients suggests treatment strategies beyond stenting and abciximab may be 
required in this high-risk subgroup 
6-Month Outcomes PTCA<75 yra PTCA >75 yrs Stent<75 yrs Stent >75 
yrs 
N 909 136 899 137 
Death 2.6%* 7.4% 2.2** 10.2% 
MACE 16.3% 24.3% 9.7% 13.9% 
Ischemic TVR 13.3% 16.2% + 6.6% 3.7% 
Disabling CVA 0.4% 0.7% 0.8% 1.5% 
All Strokes 0.8% 1.5% 1.3% 2.9% 
*p=.01 PTCA<75 vs PTCA>75yrs ; **p<.001 etent <75 vs etent >75yrs; +p<.0Ol 
PTCA>75 vs stent >75yrs 
ABSTRACTS-  Myocard ia l  In fa rc t ion  and  I schemia  289A 
1050-40 Excessive Hospital Mortality of ST Elevation Myocardial 
Infarction in Female Diabetics: Results of the MITRA 
and MIR Registries 
Anselm K. Gitt, Rudolf Schiele, Harm Wienbergen, Tobias Heer, Christine Meisenzahl, 
Martin G. Gottwik, Jochen Sangas, MITRA-Study-Group, MIR-Study-Group, Heart 
Center Ludwigshafen, Ludwigshafen, Gen'nany, Klinikum N(Jrnberg, N~mbarg, Germany. 
Background: Patients with known diabetes and acute ST-elevation myocardial infarction 
(STEMI) are on increased risk of hospital mortality. Recent studies have shown an 
increased risk in female STEMI patients. It is unknown, if female gender has an impact 
on the hospital course of diabetic STEMI patients. 
Methods: We analysed the prospective data of 6502 / 28401 (23%) STEMI-patients with 
known diabetes of the MITRA- and MIR-registries to identify the impact of female gender 
on acute treatment and hospital outcome of STEMI in diabetics. 
Results: Diabetic STEMI patients were less likely to receive reperfusion therapy (OR 
0.82, p<0.01) and B.blockers (OR 0.80, p<0.01 ) as compared to non-diabetics. Out of the 
6502 diabetic patients with STEM18043 (23%) were female. After correcting for baseline 
differences in diabetics with STEMI, female gender was an independent determinant 
against acute reperfusion therapy (OR 0. 72, 0.65-0.81) and 13-blocker therapy (OR 0.83, 
0.74-0.93). After correction for these differences in acute therapy in a muJtivariate analy- 
sis, female diabetics had a significantly increased hospital mortality as compared to male 
diabetics (OR 1.27, 1.09-1.49). 
Conclusion: Female diabetic STEMI patients were less likely to receive acute reperfu- 
sion therapy than diabetic men. Within the diabetic STEMI patients with already 
increased risk of hospital mortality compared to non-diabetics, female diabetics had a 
27% increased hospital mortality as compared to mate diabetics. 
Female diabetics Male diabetics p 
Age 75 68 <0.001 
Acute Reperfusion 34.2 % 47.5 % <0.001 
Aspirin 89.2 % 92.1% <0.001 
B-blockers 47.9 % 57.8 % <0.05 
ACE-inhibitors 62.8 % 63.7 % <0.001 
1050-41 Does Gender Independently Influence the Treatment 
and Outcomes of Patients With Early Reinfarction After 
Fibrinolysis? 
Michael C. Tiandrawid!aia, Yuling Fu, Frans Van de Weft, Christopher B. Granger, Paul 
W. Armstrong, for the ASSENT 2 Investigators, University of Alberta, Edmonton, Alberta, 
Canada. 
Despite the high-risk nature of patients who sustain in-hospital reinfarction (re-MI) after 
fibrinolytic therapy for acute myocardial infarction, surprisingly little is known about how 
gender modulates the treatment and outcomes of this important subset of patients. 
Accordingly, we analyzed the 13,028 men and 3,921 women in ASSENT-2 to examine 
this issue. 
The table provides key data according to gender of the 4.0% of patients who sustained 
re-MI (female vs. male incidence: 4.8% vs 3.7%; p = 0.002). 
Although rates of urgent revascularization were similar, women with re-MI less often 
received repeat fibrinolysis despite similar total ST elevation on the re-MI ECG and tim- 
ing of re-MI. This pattern persisted even after adjustment for baseline and bleeding prior 
to re-MI (odds ratio [OR]: 0.57, 95% confidence interval [CI]: 0.4 - 0.9). Although women 
with re-MI had higher mortality both at 30 days and 1 year, their apparent excess mortal- 
ity was eliminated after adjustment for baseline covadates (30 days OR: 1.45, 95% Ch 
0.9-2.5; 1 year OR: 0.98, 95% Ch 0.6 - 1.6). Additional adjustment for re-MI treatment 
strategy further reduced the apparent survival disadvantage in women (30 days OR: 
1.29, 95% Cl: 0.8 - 2.2; 1 year OR: 0.84, 95% Ch 0.5 - 1.4). 
We conclude that the worse outcomes in women with re-MI are largely due to their unfa- 
vorable baseline risk profile. Our results suggest a true gender bias exists in the use of 
repeat fibrinolysis. Further investigation is required to assess its impact on the worse Out- 
comes in women. 
Men (n=481) Women (n=189) p 
Age (years)* 64 (54-72) 69 (60-76) <0.001 
Hypertension 37% 61% <0.001 
Diabetes 16% 24% 0.03 
In-hospital bleeding prior to re-MI 17% 29% 0.001 
Time to re-MI (days)* 3 (1-4) 3 (1-5) 0.11 
Re-MI total ST elevation (mV)* 8 (5-14) 7 (4-13) 0.25 
Re-MI peak CK>5x normal 37% 39% 0,67 
Repeat fibrinolysis 41% 31% 0.02 
PTCA or CABG <48 hours after re-MI 34% 31% 0.47 
Death at 30 days 14% 24% 0.004 
Death at 1 year 20% 27% 0.04 
*Median (25th-75th percentiles) 
